| 000 | 01831 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517185353.0 | ||
| 264 | 0 | _c20180709 | |
| 008 | 201807s 0 0 eng d | ||
| 022 | _a1478-6362 | ||
| 024 | 7 |
_a10.1186/s13075-017-1462-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHorneff, Gerd | |
| 245 | 0 | 0 |
_aExperience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. _h[electronic resource] |
| 260 |
_bArthritis research & therapy _cNov 2017 |
||
| 300 |
_a256 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAge of Onset |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadverse effects |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadverse effects |
| 650 | 0 | 4 |
_aArthritis, Juvenile _xdrug therapy |
| 650 | 0 | 4 |
_aBiological Products _xtherapeutic use |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 |
_aEtanercept _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGermany |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInfections _xchemically induced |
| 650 | 0 | 4 |
_aInterleukin 1 Receptor Antagonist Protein _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aRegistries _xstatistics & numerical data |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aSchulz, Anna Carina | |
| 700 | 1 | _aKlotsche, Jens | |
| 700 | 1 | _aHospach, Anton | |
| 700 | 1 | _aMinden, Kirsten | |
| 700 | 1 | _aFoeldvari, Ivan | |
| 700 | 1 | _aTrauzeddel, Ralf | |
| 700 | 1 | _aGanser, Gerd | |
| 700 | 1 | _aWeller-Heinemann, Frank | |
| 700 | 1 | _aHaas, Johannes Perter | |
| 773 | 0 |
_tArthritis research & therapy _gvol. 19 _gno. 1 _gp. 256 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s13075-017-1462-2 _zAvailable from publisher's website |
| 999 |
_c27816813 _d27816813 |
||